Detalhe da pesquisa
1.
ST3GAL1 and ßII-spectrin pathways control CAR T cell migration to target tumors.
Nat Immunol
; 24(6): 1007-1019, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37069398
2.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
4.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
5.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Blood
; 139(9): 1330-1339, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570879
6.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
7.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
8.
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Future Oncol
; 17(11): 1269-1283, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33448873
9.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(1): 31-42, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30518502
10.
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
Blood
; 138(12): 1081-1085, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34041526
11.
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Expert Opin Emerg Drugs
; 23(2): 111-122, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781323
12.
Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.
Oncology (Williston Park)
; 31(5): 402-11, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28516439
13.
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.
Br J Haematol
; 188(4): e33-e36, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31845324
14.
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.
Future Oncol
; 11(10): 1543-53, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25963431
15.
Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
Curr Treat Options Oncol
; 16(7): 32, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26031546
16.
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Blood Adv
; 2024 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315832
17.
PD-1Hi CAR-T cells provide superior protection against solid tumors.
Front Immunol
; 14: 1187850, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37388744
18.
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
Blood Adv
; 7(11): 2496-2503, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689726
19.
Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.
Clin Lymphoma Myeloma Leuk
; 23(9): e260-e267, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301630
20.
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Clin Cancer Res
; 29(17): 3301-3312, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364001